Gilead (GILD) Stock Still Looks Below Fair Value As Court Backs HIV Import Block

Simply Wall St.08-21 04:35

Gilead Sciences stock has delivered very strong long term returns over the past five years, yet current valuation checks and market multiples still point to the shares screening as undervalued. With ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2661923014?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/29002-main-header/1756252861953","is_english":true,"pubTime":"2026-08-21 04:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2661923014","market":"hk","top_or_hot":-1,"title":"Gilead (GILD) Stock Still Looks Below Fair Value As Court Backs HIV Import Block","media":"Simply Wall St.","content":"<div>\n<p>Gilead Sciences stock has delivered very strong long term returns over the past five years, yet current valuation checks and market multiples still point to the shares screening as undervalued. With ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-gild/gilead-sciences/news/gilead-gild-stock-still-looks-below-fair-value-as-court-back\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gilead (GILD) Stock Still Looks Below Fair Value As Court Backs HIV Import Block</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGilead (GILD) Stock Still Looks Below Fair Value As Court Backs HIV Import Block\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-08-21 04:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-gild/gilead-sciences/news/gilead-gild-stock-still-looks-below-fair-value-as-court-back><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Gilead Sciences stock has delivered very strong long term returns over the past five years, yet current valuation checks and market multiples still point to the shares screening as undervalued. With ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-gild/gilead-sciences/news/gilead-gild-stock-still-looks-below-fair-value-as-court-back\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1430594728.SGD","symbol_name":"Eastspring Investments - Global Low Volatility Equity AS SGD","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-gild/gilead-sciences/news/gilead-gild-stock-still-looks-below-fair-value-as-court-back","article_id":"2661923014","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/29002-main-header/1756252861953"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-gild/gilead-sciences/news/gilead-gild-stock-still-looks-below-fair-value-as-court-back","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2661923014","pubTimestamp":1787258134,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Gilead Sciences stock has delivered very strong long term returns over the past five years, yet current valuation checks and market multiples still point to the shares screening as undervalued. With recent news flow focused on its HIV and oncology franchises and on legal protection of its U.S. drug pricing, investors are weighing how much of this is already reflected in the price.\n\nGilead Sciences has returned 148.1% over the past five years, which puts recent valuation questions in the...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","BBH":"VanEck Biotech ETF","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU0965508806.USD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (USD) INC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU1934455277.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"AD\" (USD) INC","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","BK4566":"资本集团","BK4585":"ETF&股票定投概念","LU0965509283.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (SGDHDG) INC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU0965509010.AUD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (AUDHDG) INC","LU1037948541.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (HKD) ACC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","CDIG":"City Different Investments Global Equity ETF","LU1934455194.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (USD) ACC","IBBQ":"Invesco Nasdaq Biotechnology ETF","BMED":"iShares Health Innovation Active ETF","BIB":"Ultra纳斯达克生物科","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU0122379950.USD":"贝莱德世界健康科学A2","TACU":"T. Rowe Price Active Core U.S. Equity ETF","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1934455863.HKD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (HKD) ACC","BK4550":"红杉资本持仓","MEDI":"HARBOR HEALTH CARE ETF","SG9999015978.USD":"利安颠覆性创新基金A","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","GILD":"吉利德科学","IBB":"生物科技指数ETF-iShares Nasdaq","LU2087621335.USD":"ALLSPRING GLOBAL FACTOR ENHANCED EQUITY \"A\" (USD) ACC","TMED":"T. Rowe Price Health Care ETF","LU0861579265.USD":"联博低波幅策略股票基金A","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","TBXU":"Direxion Daily Biotech Top 5 Bull 2X ETF","BK4588":"碎股","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","DAPP":"VanEck Digital Transformation ETF","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU1778281490.HKD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AD\" (HKD) INC","TSPA":"T. Rowe Price U.S. Equity Research ETF","SG9999015945.SGD":"LionGlobal Disruptive Innovation Fund A SGD","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","SG9999015986.USD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (USD) ACC","LU1037948897.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (HKD) INC"},"translate_title":"由于法院支持艾滋病毒进口阻止，吉利德 (GILD) 股价仍低于公允价值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BIB":0.6,"DAPP":1.5,"GILD":1.5,"IBB":0.6,"TACU":0.79,"CDIG":0.79,"MEDI":0.6,"BBH":0.6,"IBBQ":0.6,"TSPA":0.79,"TMED":0.6,"BMED":0.6,"TBXU":0.6},"content_text":"Gilead Sciences stock has delivered very strong long term returns over the past five years, yet current valuation checks and market multiples still point to the shares screening as undervalued. With recent news flow focused on its HIV and oncology franchises and on legal protection of its U.S. drug pricing, investors are weighing how much of this is already reflected in the price.  Gilead Sciences has returned 148.1% over the past five years, which puts recent valuation questions in the context of a stock that has already created substantial shareholder value. Progress in oncology and HIV treatments alongside partnerships in areas like tissue analytics can support confidence in future cash flows, while ongoing legal and regulatory risks around drug pricing and supply channels may limit how much investors are willing to pay for that growth. The broader valuation checks lean cheap, with Gilead Sciences screening as undervalued on 5 of 6 measures on Simply Wall St's valuation framework.  The issue now is whether Gilead Sciences' current share price still leaves enough upside relative to what these valuation checks suggest. Find out why Gilead Sciences' 27.6% return over the last year is lagging behind its peers. AdvertisementIs Gilead Sciences a Bargain on Sales? The price-to-sales (P/S) multiple suits Gilead Sciences because revenue is a key anchor for valuing large biopharma companies with established product franchises. Gilead Sciences trades on a P/S of 6.0x. This compares with an industry average of 11.6x for biotechs and a peer group average of 7.5x. The fair P/S ratio implied by Simply Wall St's model is 9.9x, which reflects what investors might be expected to pay for Gilead Sciences given its margins, scale and risk profile. On that basis, the stock changes hands at a sizeable discount to the modelled fair P/S, even after recent headlines around its HIV and oncology pipeline and a legal win on HIV drug imports. The gap suggests the market is pricing Gilead Sciences below what these revenue-based checks imply. On the P/S multiple, Gilead Sciences stock appears undervalued relative to both its fair ratio and sector benchmarks. NasdaqGS:GILD P/S Ratio as at Aug 2026 See what the numbers say about this price — find out in our valuation breakdown. The Gilead Sciences Narrative: What Would Justify Today's Price? Simply Wall St Narratives pick up where the Gilead Sciences valuation puzzle leaves off and spell out what growth, margin and earnings outcomes would need to hold for the stock to be worth materially more or less than today. Each one treats Gilead Sciences' fair value as a thesis about the business that you can watch over time, and they sit on Simply Wall St's Community page for investors who want to follow those stories. Community narratives on Gilead Sciences stock pull in opposite directions, with one cohort seeing clear valuation upside and another warning on execution and pricing risk. Bull case: 18% undervalued \"Gilead’s upcoming launches, including twice-yearly lenacapavir for PrEP, anito-cel cell therapy for multiple myeloma, and Trodelvy’s move into first-line triple-negative breast cancer, positively position the company to capture significantly larger addressable markets…\" Read the full Bull Case to see why Gilead Sciences could be undervalued Bear case: 15% overvalued \"Bear case: Execution risk (M&A integration, oncology competition, pricing pressure) and near-term EPS dilution.\" Read the full Bear Case to see why Gilead Sciences could be overvalued Do you think there's more to the story for Gilead Sciences? Head over to our Community to see what others are saying! The Bottom Line Gilead Sciences screens as undervalued on market multiples, which points to a discount that investors may consider significant. The key question is whether that gap reflects genuine mispricing or a sensible cushion for execution and pricing risk around its HIV and oncology franchises. From here, the call depends on whether Gilead Sciences can deliver on its product pipeline and manage regulatory and legal pressures in a way that prompts the market to reconsider how much it is willing to pay for those cash flows.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2661923014","isCrawlerRequest":true}